From: Methylation and expression of the tumour suppressor, PRDM5, in colorectal cancer and polyp subgroups
 | BRAFmutant | BRAFwild type | P value |
---|---|---|---|
N | 214 | 122 | - |
Average Age (years) | 74.1 | 67.1 | <0.0001 |
Gender - female | 139/214 (65.0%) | 49/122 (40.2%) | <0.0001 |
Tumour Location (Proximal) | 164/192 (85.4%) | 28/117 (23.9%) | <0.0001 |
AJCC stage I/II | 110/170 (64.7%) | 58/111 (52.3%) | <0.05 |
AJCC stage III/IV | 60/170 (35.3%) | 53/111 (47.7%) | |
Mucinous | 37/96 (38.5%) | 3/42 (7.1%) | <0.0001 |
Differentiation (poor) | 38/96 (39.6%) | 12/42 (28.6%) | 0.2 |
MSI High | 120/214 (56.1%) | 0 | - |
CIMP High | 154/205 (75.1%) | 3/121 (2.5%) | <0.0001 |
p53 Mutation | 29/107 (27.1%) | 40/80 (50.0%) | 0.002 |
KRAS Mutation | 0 | 38/80 (47.5%) | - |
PRDM5 Methylation | 77/214 (36.0%) | 4/122 (3.3%) | <0.0001 |
PRDM5 PMR | 27 | 3 | <0.0001 |
Nuclear Beta-Catenin | 36/92 (39.1%) | 36/42 (85.7%) | <0.0001 |